Abstract:

The biomimetic structure of scaffolds alone has certain limitations on regulating cell behavior and bone tissue regeneration, so the combination of biomimetic scaffolds and nano-drug delivery has become an effective solution. A serial of 3D porous PLA/CS/GO/ASA biomimetic composite scaffolds with different ASA contents were successfully prepared by phase separation method. The addition of ASA destroyed the formation of PLA spherulite structure but had little effect on the structure of biomimetic micro-nano fiber. With the increasing of ASA, the hydrophilicity of drug-loaded scaffolds was improved in the experimental range, but the porosity showed a trend of decreasing first and then increasing, all of which were more than 80%. The hemolysis rate and platelet adhesion experiments showed that the scaffold material with good blood compatibility could be obtained by controlling the ASA content below 5%. Thecell proliferation experiments in vitro showed that the prepared drug-loaded scaffolds had cytocompatibility. Low ASA content could promote the proliferation of MC3T3-E1 cells, and high ASA content had a certain inhibitory effect on MC3T3-E1 cells. The sustained release experiments showed that the PLA/CS/GO/ASA drug-loading biomimetic composite scaffold had good sustained release performance.

Key words: drug-loaded, biomimetic scaffolds, hemocompatibility, cytocompatibility, sustained release

摘要：

单纯的支架仿生结构在调节细胞行为和骨组织再生方面有一定的局限性，因此将仿生支架与纳米给药相结合成为一种提高支架功能的有效解决方案。本文采用相分离法成功制备了不同ASA（阿司匹林）含量的三维多孔PLA/CS/GO/ASA载药仿生复合支架。ASA的添加破坏了PLA球晶结构的形成，但对仿生微、纳米纤维结构的影响不大；实验范围内随ASA含量的增加，载药支架亲水性能有所改善，但孔隙率呈先减后增的趋势，均大于80%；溶血率和血小板黏附实验表明，控制ASA含量在5%以下可获得具有良好血液相容性的支架材料；体外细胞增殖实验则表明所制备的载药支架具有细胞相容性；低ASA含量可以促进MC3T3-E1细胞增殖，高含量的ASA对MC3T3-E1细胞有一定的抑制作用；药物缓释实验表明PLA/CS/GO/ASA载药仿生复合支架具有良好的ASA缓释性能。

关键词: 载药, 仿生支架, 血液相容性, 细胞相容性, 缓释